Phase 4 N=76 Early Surgery Versus Conventional Treatment in Infective Endocarditis
Endocarditis
Primary: Number of Participants With In-hospital Death or Clinical Embolic Events — 9; 1 participants — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,010 Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.
Sick Sinus Syndrome · Complete Heart Block · Syncope
Primary: Number of Patients With a Major Cardiac Implantable Electronic Devices (CIED) Infection — 5; 6 Participants
Phase 3 N=102 Periodontal Infection and Endothelial Dysfunction
Periodontitis
Primary: Brachial Artery Flow-mediated Dilation — 10.2; 10.3; 13.1; 8.1 Percentage of dilatation of brachial art — p=0.98
N/A N=18 Role of Infected Blood Dendritic Cells in Heart Disease Risk
Chronic Periodontitis
Primary: Frequency of Blood Dendritic Cells From Baseline — 12; 14 % MFI
N/A N=29 Proteolytic Enzyme Induction Within the Human Myocardial Interstitium
Heart Disease
Primary: Pulmonary Vascular Resistance — 153.8; 213.0; 174.6; 123.5 dyne*second/centimeter˄5 — p=<0.05
Phase 2 N=10 Interleukin-1 Receptor Antagonist for the Treatment of Heart Failure in Patients With Left Ventricular Assist Devices
Heart Failure
Primary: Biologic Efficacy: Inflammation Marker - C-Reactive Protein — 2.5; 0.6; 0.6 mg/dL
N/A N=72 Comparison of Intracardiac Echocardiography and Transesophageal Echocardiography
Atrial Fibrillation · Atrial Flutter
Primary: Intracardiac and Transesophageal Echo Results — 71; 69; 4; 1 participants
Phase 4 N=6,983 World-wide Randomized Antibiotic Envelope Infection Prevention Trial
CIED Related Infection
Primary: 12 Month Kaplan-Meier Estimate of Major CIED Infection Rate — 0.7; 1.2 Percentage of subjects — p=0.0406
N/A N=24 Long-term Monitoring of Patients With Cardiac Amyloidosis With Implantable Event Monitors
TTR Cardiac Amyloidosis
Primary: Sudden Death — 0 Participants
N/A N=61 Cardioband With Transfemoral Delivery System
Mitral Regurgitation
Primary: Number of Participants With Major Serious Adverse Events and Serious Adverse Device Effects — 2; 1; 2; 4 Participants
N/A N=1,615 TYRX™ Envelope for Prevention of Infection Following Replacement With a CRT or ICD
Cardiac Implantable Electronic Device Infection
Primary: Major CIED Infection — 0.6; 1.0; 0.7 percentage of Participants — p=0.0023
Phase 4 N=19 Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)
Cardiac Allograft Vasculopathy
Primary: Macitentan: Nitroglycerin (NTG) Luminal Dilation Ratio as Proportion of Vasomotor Tone Attributable to Endothelin-1 (ET-1) — 0.33; 0.30 ratio
Phase 3 N=1,426 Edoxaban Compared to Standard Care After Heart Valve Replacement Using a Catheter in Patients With Atrial Fibrillation (ENVISAGE-TAVI AF)
Atrial Fibrillation
Primary: Number of Participants Who Experienced Net Adverse Clinical Events (Adjudicated Data) Based on ISTH Criteria in Participants Taking Edoxaban vs VKA — 170; 157…
N/A N=26 COMMENCE Pulmonary: Clinical Evaluation of Edwards Pericardial Aortic Bioprosthesis (Model 11000A) for Pulmonary Valve Replacement
Pulmonary Valve Insufficiency · Pulmonary Valve Degeneration · Congenital Pulmonary Valve Abnormality
Primary: Percentage of Subject's With Freedom From Device or Procedure Related Death and/or Reoperation at 1-year Post-implant. — 100.0 percentage of subjects
Phase 4 N=87 Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
Cardiovascular Diseases · Hepatitis C · Hiv
Primary: Change in Cardiovascular Disease Risk From Baseline to After Functional Cure of Hepatitis C, as Measured by High-sensitivity C-reactive Protein — 0.6; 0 mg/L
N/A N=516 EDWARDS INTUITY Valve System FOUNDATION Study
Aortic Valve Disease · Aortic Stenosis · Rapid Deployment Valves
Primary: Subject's Average Time Spent on Cardiopulmonary Cross Clamp — 59.7 minutes
Phase 3 N=216 Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
Invasive Candidiasis
Primary: Percentage of Participants With Global Treatment Response Success at End of Treatment — 69.5 percentage of participants
Phase 4 N=40 Demonstration of Reverse Remodeling Effects of Entresto. Using Echocardiography Endocardial Surface Analysis
Heart Failure
Primary: Change From Baseline in LV Remodeling 2D End-Diastolic Diameter (cm) — 6; 6 cm — p=<0.001
Phase 2 N=30 Anakinra to Prevent Adverse Post-infarction Remodeling (2)
Acute Myocardial Infarction · Heart Failure
Primary: Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular End-systolic Volume Indices — 1.5; 1.0 mL/m2 — p=<0.05
N/A N=177 Diabetes and Lipid Accumulationand Heart Transplant
Diabetes Mellitus · Heart Failure
Primary: Myocyte Lipid Accumulation as Oil Red-O Positive Biopsie — 54; 21; 0 Endomyocardial Biopsies
N/A N=90 Transcatheter Valve Implantation in Patients With Dysfunctional Left and Right Sided Heart Valves
Eisenmenger Syndrome
Primary: Number of Participants Who Developed Infective Endocarditis — 9 participants